We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The −374 A allele of the receptor for advanced glycation end products ( RAGE) gene promoter is a protective factor against cardiovascular lesions in type 2 diabetes mellitus patients.
- Authors
Picheth, Geraldo; Costantini, Costantino O.; Pedrosa, Fábio O.; Leme da Rocha Martinez, Tania; Maltempi de Souza, Emanuel
- Abstract
Background: Polymorphisms of the receptor for advanced glycation end products ( RAGE) gene have been associated with diabetes, coronary artery disease (CAD) and inflammatory processes. The –374T>A RAGE gene promoter polymorphism was shown to affect gene transcription. The aim of this study was to evaluate the association of the –374T>A polymorphism with the severity of CAD in patients with or without type 2 diabetes mellitus. Methods: We studied 246 Euro-Brazilians with angiographically defined CAD (stenosis >50%), comprising type 2 diabetic (n=98) and non-diabetic subjects (n=148). Genotyping was performed by PCR-restriction fragment length polymorphism using Tsp509I restriction enzyme. Results: The AA genotype was associated with a significant decrease in CAD severity estimated by the number of diseased vessels (1.43±0.5 vs. 2.49±1.1; p=0.002) and the Duke score (27.3±10.8 vs. 49.3±20.1; p=0.001) only in the group of CAD subjects with type 2 diabetes mellitus. The protective effect of the AA genotype against severity of CAD was not observed in the non-diabetic group. Conclusion: This result confirms that the –374 AA genotype of the RAGE gene promoter is a protective factor against the severity of CAD lesions in type 2 diabetic patients. Clin Chem Lab Med 2007;45:1268–72.
- Subjects
GENETIC polymorphisms; CARDIOVASCULAR diseases; TYPE 2 diabetes; CORONARY disease; CLINICAL chemistry; CLINICAL pathology
- Publication
Clinical Chemistry & Laboratory Medicine, 2007, Vol 45, Issue 10, p1268
- ISSN
1434-6621
- Publication type
Article
- DOI
10.1515/CCLM.2007.273